[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354802-105":59,"doc-detail-354802-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","canakinumab-or-emavusertib-for-anemia-in-lower-risk-mds-results-of-the-canfire-and-lucas-phase-2-open-label-multicenter-trials","Canakinumab or emavusertib for anemia in lower-risk MDS - results of the CANFIRE and LUCAS phase 2 open-label multicenter trials","","Lower-risk myelodysplastic syndromes (LR-MDS) and related MDS/MPN are driven by ineffective hematopoiesis and increased progression risk to AML, with inflammatory signaling—especially IL-1β and IRAK4/TLR pathways—contributing to suppressed hematopoietic stem and progenitor function. Phase 2, open-label CANFIRE and LUCAS trials assessed canakinumab or emavusertib in ESA-refractory/intolerant patients or ESA-eligible subgroups. Neither trial met the primary hematologic improvement endpoint by planned treatment, and both programs were terminated early due to inadequate recruitment and interim futility.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/canakinumab-or-emavusertib-for-anemia-in-lower-risk-mds-results-of-the-canfire-and-lucas-phase-2-open-label-multicenter-trials/354802/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/canakinumab-or-emavusertib-for-anemia-in-lower-risk-mds-results-of-the-canfire-and-lucas-phase-2-open-label-multicenter-trials/354802.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main objective of the CANFIRE and LUCAS phase 2 trials?","Question",{"text":112,"@type":113},"To determine the efficacy and safety of canakinumab (CANFIRE) or emavusertib (LUCAS) in patients with lower-risk MDS or MDS/MPN with anemia.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were canakinumab and emavusertib administered?",{"text":117,"@type":113},"CANFIRE patients received canakinumab 200 mg subcutaneously every 21 days for up to eight cycles in the first six months. LUCAS patients received emavusertib 200–300 mg orally twice daily for 21 days in up to four 28-day cycles.",{"name":119,"@type":110,"acceptedAnswer":120},"Did either trial achieve its primary endpoint?",{"text":121,"@type":113},"No. No patients in CANFIRE or LUCAS achieved the primary hematologic improvement endpoint by the end of the planned treatment period.",{"name":123,"@type":110,"acceptedAnswer":124},"What were the safety outcomes and why were the trials ended early?",{"text":125,"@type":113},"Canakinumab was well tolerated in CANFIRE with no reported serious adverse events and no deaths, while LUCAS reported serious adverse events and deaths. Both trials were terminated early due to inadequate recruitment and pre-planned interim futility analysis, respectively.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},354802,1790601840,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","A Nature Portfolio journal  \n[https://doi.org/10.1038/s43856-026-01885-z](https://doi.org/10.1038/s43856-026-01885-z)  \nCanakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials  \n Check for updates  \n\n| A list of authors and their afﬁliations appears at the end of the paper |  |  |\n| --- | --- | --- |\n| Abstract |  | Plain language summary |\n| Background Dysregulated innate immune signaling promotes inﬂammatory suppression of hematopoietic stem and progenitor cell function, contributing to ineffective erythropoiesisin myelodysplastic neoplasms (MDS) . The phase 2, open-label CANFIRE and LUCAS trials aimed to determine the efﬁcacy and safety of canakinumab or emavusertib, respectively, inpatients with lower-risk MDS (LR-MDS) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) .\u003Cbr>Methods Patients in CANFIRE were refractory, intolerant to, or ineligible for erythropoiesisstimulating agent(ESA)treatment and received canakinumab200 mg subcutaneously every 21days for upto eight cycles within theﬁrst six months oftreatment. Patients in LUCAS were either refractory or intolerant to ESAs (cohort A) or ESA-naïve with serum erythropoietin levels >200 U/L (cohort B); all patients received emavusertib 200–300 mg orally twice daily for 21 days in up to four 28-day cycles. The primary endpoint for both trials was hematologic improvement–erythroid per International Working Group 2018 criteria at the end of the planned treatment period. CANFIRE was [registered at ClinicalTrials.gov](registered at ClinicalTrials.gov) (NCT05237713; registered January 21, 2022) . LUCAS was registered in the EU Clinical Trials Register (EudraCT 2020-003986-20; registered March 15, 2021) [and at ClinicalTrials.gov](and at ClinicalTrials.gov)[ ](and at ClinicalTrials.gov)(NCT05178342; registered November 2, 2021) .\u003Cbr>Results Here we show that of 11 patients enrolled in CANFIRE and 36 patients enrolled in LUCAS, no patients in either trial achieved the primary endpoint. Canakinumab treatment was well-tolerated, with no reported serious adverse events (SAEs) and no patients died in the CANFIRE trial. In the LUCAS trial, 15 patients reported SAEs, and four patients died. CANFIRE and LUCAS were terminated early due to inadequate patient recruitment and after a pre-planned interim futility analysis, respectively.\u003Cbr>Conclusions Inhibition of IL-1β orIRAK4 signaling with canakinumab or emavusertib did not result in hematologic improvement in patients with LR-MDS. |  | There is evidence that the drugs canakinumab and emavusertib could be useful for treating patients with certain blood cancers, speciﬁcally lower-risk myelodysplastic neoplasms (LR-MDS) or myelodysplastic/myeloproliferative neoplasms (MDS/ MPN) . The CANFIRE and LUCAS trials were carried out to see whether canakinumab oremavusertibare safe and effective when used for the treatment of patients with LR-MDS or MDS/MPN. Patients in the CANFIRE trial received canakinumab, and patients in the LUCAS trial received emavusertib. The primary endpoint of both trials was a reduction in the number of blood transfusions a patient needed and/or an increase in their hemoglobin level. No patients in either trial achieved the primary endpoint, and neither canakinumab nor emavusertib alone appears to besufﬁcient to treat patients with LR-MDS. Although neither drug was effective when used alone, future studies should investigate combination treatments, alternative treatment approaches, potentially longer treatment durations, and better selection of patients who are most likely to beneﬁt. |\n| Myelodysplastic neoplasms(MDS)and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are hematologic malignancies characterized by ineffective hematopoiesis and an increased risk of progression to acute myeloid leukemia(AML)1–6. Thereis increasing evidence to suggest that the pathogenesis of these disorders involves the upregulation of inﬂammatory signaling","cbCaiaYd8eDFkjSX","https://ap.wps.com/l/cbCaiaYd8eDFkjSX","pdf",1865013,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Study design and rationale\n## Study design (CANFIRE and LUCAS)\n## Biological rationale: IL-1β/IRAK4 signaling","[{\"question\":\"What was the main objective of the CANFIRE and LUCAS phase 2 trials?\",\"answer\":\"To determine the efficacy and safety of canakinumab (CANFIRE) or emavusertib (LUCAS) in patients with lower-risk MDS or MDS/MPN with anemia.\"},{\"question\":\"How were canakinumab and emavusertib administered?\",\"answer\":\"CANFIRE patients received canakinumab 200 mg subcutaneously every 21 days for up to eight cycles in the first six months. LUCAS patients received emavusertib 200–300 mg orally twice daily for 21 days in up to four 28-day cycles.\"},{\"question\":\"Did either trial achieve its primary endpoint?\",\"answer\":\"No. No patients in CANFIRE or LUCAS achieved the primary hematologic improvement endpoint by the end of the planned treatment period.\"},{\"question\":\"What were the safety outcomes and why were the trials ended early?\",\"answer\":\"Canakinumab was well tolerated in CANFIRE with no reported serious adverse events and no deaths, while LUCAS reported serious adverse events and deaths. Both trials were terminated early due to inadequate recruitment and pre-planned interim futility analysis, respectively.\"}]","Canakinumab or emavusertib for anemia in lower-risk MDS - results of the CANFIRE and LUCAS phase 2 open-label multicenter trials | PDF",1790114079,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df73a673e88a0d5c7ee02b743e0e71dc.webp",983,1305,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a6dd0d6096d806671b377ef8ca541a2.webp",982,1304,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51382f43ccbcbf8143c450bf2f582134.webp",981,1303,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77461e05f611692cf00b3bda9ccfbf3c.webp",980,1301]